JPSIM Journal of Pakistan Society of Internal Medicine J Pak Soc Intern Med 2709-8729 2710-0804 Pakistan Society of Internal Medicine 10.70302/jpsim.v4i2.2323 jpsim.v4i2.2323 Original Research Assessment of Clinical Efficacy of Early Use of Remdesivir in The Patients of COVID-19 Pneumonia Mahmood Atif Khan Asma afzal.a3s3@gmail.com * Shahbaz Ayesha Pervaiz Saira Department of Pulmonology Fatima Memorial Hospital *Correspondence: Asma Khan (afzal.a3s3@gmail.com) 02 06 2023 2023 4 2 111 115 18 02 2023 12 04 2023 Copyright © 2023 The Author(s) 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective

Primary objective of the study is to evaluate the clinical efficacy of early use of Remdesivir in reducing the progression and severity of Covid-19 pneumonia.

 Methodology

This retrospective study was undertaken in Pulmonology department, Fatima Memorial Hospital, Lahore. After taking history and doing physical examination, loading dose of 200mg intravenous Remdesivir was given to the 350 patients of COVID-19 pneumonia followed by 100mg intravenous dose given once a day for five days. During treatment assessment of clinical efficacy of Remdesivir was evaluated along with viral clearance rate and evaluation of side effects of therapy. These were documented on preformed Performa.

 Results

The results showed 99.9% efficacy in patients with Covid-19 pneumonia who were treated with early Remdesivir. Paired sample t-test showed statistical significant results in radiological findings and oxygen saturation pre and post Remdesivir therapy. Almost all the clinical symptoms got relieved after therapy. Drug related side effects were reported in 21 individuals (6%).

 Conclusion

The early introduction of drug Remdesivir to the treatment of Covid-19 PCR positive patients has been suggested as a more efficacious strategy for treating Covid-19 pneumonia.

 Keywords Remdesivir Covid-19 anti-viral References Halimi V, Daci A, Stojanovska S, Panovska-Stavridis I, Stevanovic M, Filipce V, Grozdanova A. Current regulatory approaches for accessing potential COVID-19 therapies. J Pharm Policy Pract. 2020;13(1):1-4. National Library of Medicine (US). Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19). [cited 2023 February 4]. Available from: [https://www.clinicaltrials.gov/ct2/show/NCT04323761?term=remdesivir&type=Expn&cond=Covid-19&draw=2&rank=1]. Food and Drug Administration (FDA). FDA combating covid-19 with therapeutics. [Internet]. [cited 2023 February 4]. Available from: [https://www.fda.gov/media/136832/download]. Medicines and Healthcare products Regulatory Agency (MHRA). MHRA issues a scientific opinion for the first medicine to treat COVID-19 in the UK - GOV.UK [Internet]. [cited 2023 February 4]. Available from: [https://www.gov.uk/government/news/mhra-supports-the-use-of-remdesivir-as-the-first-medicine-to-treat-covid-19-in-the-uk]. European Medicines Agency (EMA). First COVID-19 treatment recommended for EU authorization. European Medicines Agency. [cited 2023 February 4]. Available from: [https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation]. Madsen LW. Remdesivir for the Treatment of Covid-19-Final Report. N Engl J Med. 2020;338(19):1813-26. Antinori S, Cossu MV, Ridolfo AL, Rech R, Bonazzetti C, Pagani G, et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and non- ICU patients: clinical outcome and differences in post- treatment hospitalisation status. Pharmacol Res. 2020;158(8):104899. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020;382(24):2327–36. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med Overseas Ed 2020; 383(19):1827-37. Beigel JH, Tomashek KM, Dodd LE. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med. 2020;10.1056/NEJMoa2007764 US Food and Drug Administration. Coronavirus (COVID-19) update: FDA issues emergency useauthorization for potential COVID-19 treatment. [Published May 1, 2020. Accessed August 10, 2022]. [https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment] European Medicines Agency. First COVID-19treatment recommended for EU authorization. [Published June 25, 2020. Accessed August 10,2022]. [https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation]